WOBURN, Mass., Feb. 9, 2026 — Biofrontera Inc. announced positive top-line results from its multicenter Phase 3 clinical trial evaluating Ameluz® photodynamic therapy (PDT) using the red-light RhodoLED® platform for the treatment of actinic keratoses (AK) on the extremities, neck, and trunk. The randomized, double-blind, vehicle-controlled study met its primary endpoint, demonstrating statistically significant superiority of Ameluz® PDT over vehicle therapy and reinforcing its clinical utility beyond currently approved anatomical treatment areas.
Science Significance
The Phase 3 trial validates the efficacy of field-directed Ameluz® PDT in treating mild-to-moderate actinic keratoses across broader body regions. The study enrolled 172 patients randomized 4:1 to receive Ameluz® gel or vehicle gel prior to photodynamic activation. The primary endpoint — subject complete clearance of treated lesions — was achieved in 45.6% of Ameluz®-treated patients versus 16.7% in the control arm, demonstrating strong therapeutic effect. Lesion clearance rates reached over 73% in the full analysis set, with even higher responses in per-protocol populations. The therapy also delivered favorable cosmetic outcomes, with investigators and patients reporting high satisfaction scores, highlighting its dual therapeutic and dermatologic benefit profile.
Regulatory Significance
Achievement of the primary endpoint positions Biofrontera to pursue regulatory label expansion through a supplemental New Drug Application (sNDA) submission to the U.S. FDA. Current approvals for Ameluz® PDT are concentrated on facial and scalp lesions; positive Phase 3 evidence may extend indications to additional sun-exposed anatomical sites. The trial’s randomized, double-blind design and long-term follow-up strengthen its regulatory evidentiary value. Successful review could broaden treatment guidelines and reinforce photodynamic therapy’s role in dermatologic oncology prevention strategies, particularly for pre-cancerous lesions with malignant transformation risk.
Business Significance
Advertisement
Label expansion into extremities, neck, and trunk indications would substantially enlarge Ameluz®’s commercial addressable market. Actinic keratosis is the most frequently diagnosed dermatologic condition in U.S. clinical practice, creating strong demand for scalable field-directed therapies. Expanded use across high-burden lesion areas may drive product utilization, device adoption, and clinic procedural revenue. As a drug-device combination therapy, Ameluz® PDT also strengthens Biofrontera’s competitive positioning within the photodynamic therapy segment and supports lifecycle management strategies for dermatology portfolios.
Patients’ Significance
Actinic keratosis represents a pre-cancerous condition with potential progression to squamous cell carcinoma if untreated, making effective lesion clearance clinically critical. Many patients present with widespread lesions across multiple body sites, creating unmet need for therapies capable of treating large surface areas. Field-directed Ameluz® PDT enables treatment of clustered lesions while preserving surrounding tissue integrity. Favorable cosmetic outcomes further enhance patient acceptance, particularly for visible or sun-damaged areas. Expanded therapeutic access could improve prevention of invasive skin cancer development.
Policy Significance
Advances in non-invasive dermatologic oncology interventions align with preventive healthcare policy priorities. Early treatment of actinic keratoses reduces long-term cancer burden, procedural costs, and surgical intervention rates. Health systems increasingly emphasize field therapy approaches that combine efficacy, safety, and cosmetic preservation. Regulatory support for photodynamic therapy expansion may influence dermatology treatment guidelines, reimbursement coverage, and preventive oncology frameworks focused on reducing ultraviolet-related malignancies.
With statistically significant Phase 3 outcomes and regulatory submission plans underway, Ameluz® PDT advances toward broader clinical adoption in dermatologic oncology prevention. The combination of high lesion clearance, strong cosmetic outcomes, and scalable field treatment capability underscores its potential to redefine actinic keratosis management across multiple anatomical regions. Regulatory review and label expansion decisions will be key determinants of its future clinical and commercial trajectory.
Source: Biofrontera Inc press release
